HC Wainwright & Co. Reiterates Buy on WAVE Life Sciences, Maintains $8 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on WAVE Life Sciences (NASDAQ:WVE) and maintained an $8 price target.
May 24, 2023 | 11:16 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on WAVE Life Sciences and maintained an $8 price target.
The reiteration of a Buy rating and maintenance of an $8 price target by HC Wainwright & Co. analyst Andrew Fein indicates a positive outlook for WAVE Life Sciences. This news is likely to have a positive impact on the stock price in the short term as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100